NASDAQ:LXRX - Lexicon Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.26 -0.09 (-2.68 %) (As of 01/27/2020 04:00 PM ET) Add Compare Today's Range$3.24Now: $3.27▼$3.4050-Day Range$3.26MA: $4.20▼$5.2352-Week Range$1.13Now: $3.27▼$8.39Volume705,276 shsAverage Volume933,959 shsMarket Capitalization$346.98 millionP/E Ratio2.40Dividend YieldN/ABeta1.02 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase III clinical trials for the treatment of type 1 and type 2 diabetes; LX9211, which is in Phase Ib clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:LXRX Previous SymbolNASDAQ:LEXG CUSIP52887210 CIK1062822 Webhttp://www.lexpharma.com/ Phone281-863-3000Debt Debt-to-Equity Ratio1.42 Current Ratio8.11 Quick Ratio8.01Price-To-Earnings Trailing P/E Ratio2.40 Forward P/E Ratio3.23 P/E GrowthN/A Sales & Book Value Annual Sales$63.21 million Price / Sales5.49 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-13.06Profitability EPS (Most Recent Fiscal Year)($1.14) Net Income$-120,550,000.00 Net Margins49.78% Return on Equity2,372.40% Return on Assets53.91%Miscellaneous Employees202 Outstanding Shares106,272,000Market Cap$346.98 million Next Earnings Date3/11/2020 (Estimated) OptionableOptionable Receive LXRX News and Ratings via Email Sign-up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:LXRX Rates by TradingView Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions What is Lexicon Pharmaceuticals' stock symbol? Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX." How were Lexicon Pharmaceuticals' earnings last quarter? Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its earnings results on Thursday, November, 7th. The biopharmaceutical company reported $2.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.31 by $0.80. The biopharmaceutical company had revenue of $294.45 million for the quarter, compared to analysts' expectations of $12 million. Lexicon Pharmaceuticals had a return on equity of 2,372.40% and a net margin of 49.78%. The firm's quarterly revenue was up 4124.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.26) EPS. View Lexicon Pharmaceuticals' Earnings History. When is Lexicon Pharmaceuticals' next earnings date? Lexicon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Lexicon Pharmaceuticals. What price target have analysts set for LXRX? 6 Wall Street analysts have issued 1 year target prices for Lexicon Pharmaceuticals' stock. Their forecasts range from $3.00 to $17.00. On average, they anticipate Lexicon Pharmaceuticals' stock price to reach $7.00 in the next year. This suggests a possible upside of 114.4% from the stock's current price. View Analyst Price Targets for Lexicon Pharmaceuticals. What is the consensus analysts' recommendation for Lexicon Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lexicon Pharmaceuticals. What are Wall Street analysts saying about Lexicon Pharmaceuticals stock? Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock: 1. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (1/14/2020) 2. Needham & Company LLC analysts commented, "Lexicon reported 1Q19 U.S. Xermelo sales of $6.7M, below our $8.0M est. Mgmt reiterated 2019 guidance for 20+% y/y U.S. sales growth. Sanofi and Lexicon announced Zynquista approval for by EMA 4/26/19. Lexicon is entitled to a milestone payment in 2Q19 tied to the approval, which we estimate to be around $30M. Discussions w/ FDA around CRL in T1D are planned. No guidance on timing. We previously removed the revenue stream from our model. The first of several Phase 3 T2D trials are expected to generate results beginning in 2Q19 (metformin combination first). We believe the stock is likely to become more attractive if Zynquista is sufficiently differentiated from SGLT2 drugs in T2D, particularly around renal impairment. Maintain HOLD." (5/2/2019) Has Lexicon Pharmaceuticals been receiving favorable news coverage? News coverage about LXRX stock has been trending somewhat negative on Monday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Lexicon Pharmaceuticals earned a news impact score of -1.4 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Lexicon Pharmaceuticals. Are investors shorting Lexicon Pharmaceuticals? Lexicon Pharmaceuticals saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 13,580,000 shares, an increase of 17.8% from the December 31st total of 11,530,000 shares. Based on an average trading volume of 1,370,000 shares, the short-interest ratio is currently 9.9 days. Approximately 13.2% of the shares of the stock are sold short. View Lexicon Pharmaceuticals' Current Options Chain. Who are some of Lexicon Pharmaceuticals' key competitors? Some companies that are related to Lexicon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Lexicon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), Progenics Pharmaceuticals (PGNX), Orexigen Therapeutics (OREX), Iovance Biotherapeutics (IOVA), Geron (GERN) and Novavax (NVAX). Who are Lexicon Pharmaceuticals' key executives? Lexicon Pharmaceuticals' management team includes the folowing people: Mr. Lonnel Coats, Pres, CEO & Director (Age 54)Mr. Jeffrey L. Wade, Exec. VP of Corp. & Admin. Affairs and CFO (Age 54)Dr. Pablo Lapuerta, Exec. VP & Chief Medical Officer (Age 56)Dr. Praveen Tyle, Exec. VP of R&D (Age 59)Mr. Alexander A. Santini, Exec. VP & Chief Commercial Officer (Age 60) Who are Lexicon Pharmaceuticals' major shareholders? Lexicon Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.35%), Strs Ohio (0.12%), California Public Employees Retirement System (0.10%) and Virginia Retirement Systems ET AL (0.03%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Institutional Ownership Trends for Lexicon Pharmaceuticals. Which institutional investors are selling Lexicon Pharmaceuticals stock? LXRX stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Lexicon Pharmaceuticals. Which institutional investors are buying Lexicon Pharmaceuticals stock? LXRX stock was purchased by a variety of institutional investors in the last quarter, including Strs Ohio, Virginia Retirement Systems ET AL and California Public Employees Retirement System. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Insider Buying and Selling for Lexicon Pharmaceuticals. How do I buy shares of Lexicon Pharmaceuticals? Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Lexicon Pharmaceuticals' stock price today? One share of LXRX stock can currently be purchased for approximately $3.27. How big of a company is Lexicon Pharmaceuticals? Lexicon Pharmaceuticals has a market capitalization of $346.98 million and generates $63.21 million in revenue each year. The biopharmaceutical company earns $-120,550,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Lexicon Pharmaceuticals employs 202 workers across the globe.View Additional Information About Lexicon Pharmaceuticals. What is Lexicon Pharmaceuticals' official website? The official website for Lexicon Pharmaceuticals is http://www.lexpharma.com/. How can I contact Lexicon Pharmaceuticals? Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000. MarketBeat Community Rating for Lexicon Pharmaceuticals (NASDAQ LXRX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 427 (Vote Outperform)Underperform Votes: 412 (Vote Underperform)Total Votes: 839MarketBeat's community ratings are surveys of what our community members think about Lexicon Pharmaceuticals and other stocks. Vote "Outperform" if you believe LXRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LXRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: How much money do you need to begin day trading?
